Medical Education Library

Optimizing the Use of Injectable Therapies for Type 2 Diabetes

This supplement was sponsored by Primary Care Education Consortium and Primary Care Metabolic Group and is supported by funding from Novo Nordisk, Inc. It was edited and peer reviewed by The Journal of Family Practice.
Author and Disclosure Information

 

The growing importance of self-injectable medications for the treatment of type 2 diabetes mellitus (T2DM) parallels that for other diseases. This is an especially significant trend, since patients are increasingly self-managing their diseases in the outpatient setting. This makes it necessary for primary care physicians to become more familiar with the role and use of injectable agents for T2DM and to overcome the negative perceptions of injectable therapies.

Recommended Reading

Guideline authors, AHA-ACC leaders confident in risk calculator
MDedge Family Medicine
Gene variant ups chronic kidney disease risk, speeds progression in African Americans
MDedge Family Medicine
FDA lifts rosiglitazone prescribing restrictions
MDedge Family Medicine
Chelation plus vitamins halved cardiovascular events in diabetics
MDedge Family Medicine
Obese and overweight adults lost significant weight on vegetarian, vegan diets
MDedge Family Medicine
Self-management of type 2 diabetes? Yes!
MDedge Family Medicine
Point/Counterpoint – Should the IADPSG criteria for diagnosing gestational diabetes be adopted now worldwide?
MDedge Family Medicine
Analysis: No such thing as ‘benign’ obesity
MDedge Family Medicine
Gastric banding benefited overweight, not just obese in type 2 diabetes
MDedge Family Medicine
Heart failure exacerbation by saxagliptin called ‘real’
MDedge Family Medicine